The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment.

Authors :: Alberton F
Nozza S
Raccagni AR
Galli L
Spagnuolo V
Bossolasco S
Cernuschi M
Canetti D
Hasson H
Castagna A
Gianotti N
Source :: Journal of medical virology [J Med Virol] 2023 Jan; Vol. 95 (1), pp. e28330.
Publication Year :: 2023

Subjects :: Humans
Rilpivirine therapeutic use
Pyridones therapeutic use
Anti-HIV Agents therapeutic use
HIV Infections drug therapy

Full Text Access

Tools